Genmab is a large biotech headquartered in Denmark. Over the past three years, Genmab has been involved in 3 licensing and acquisition transactions, with a primary focus on Antibodies (1 deal). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
0
Active Trials
50
Top Modality
Antibodies
Focus Area
Solid Tumors
Therapeutic areas and modalities where Genmab is most active based on deal history and clinical trial data.
Key indicators of Genmab's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
Genmab has 50 active clinical trials across 6 development phases.
1
Phase 4
1
Unknown
11
Phase 1
1
Phase 1/2
14
Phase 2
22
Phase 3
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Genmab is a large biotech company based in Denmark that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Genmab ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Genmab include Solid Tumors (27 deals and trials), Hematological Malignancies (15 deals and trials), Oncology (2 deals and trials), and Other (1 deal and trial). In terms of modality, Genmab has shown particular interest in antibodies, bispecific antibodies, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Genmab and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Genmab's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.